Skip to main content

Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.

Publication ,  Journal Article
Foon, KA; Walther, PJ; Bernstein, ZP; Vaickus, L; Rahman, R; Watanabe, H; Sweeney, J; Park, J; Vesper, D; Russell, D
Published in: J Immunother (1991)
April 1992

High-dose recombinant interleukin-2 (rIL-2) results in tumor responses in patients with metastatic renal cell carcinoma ranging from 9 to 31%. Continuous infusion regimens of rIL-2 may be less toxic and may result in greater in vivo lymphokine-activated killer (LAK) cell production. The current trial used a continuous infusion of rIL-2 with ex vivo LAK cells. These cells were pretreated with phenylalanine methyl ester to remove monocytes to allow cell culture at higher concentrations. Twenty-three patients were entered into the trial. Two patients had complete responses (9%) lasting 15+ and 20+ months. Four patients had partial responses (17%) of 9+, 6+, 3, and 3 months, respectively. One partial responder at 9+ months had only minimal residual retroperitoneal disease that may represent scar tissue. All responders had prior nephrectomies. All but one of the responding patients completed a full cycle of rIL-2 at the highest (starting) dose, 6 x 10(6) U/m2. This rIL-2/LAK regimen appears to be an effective therapy for metastatic renal cell carcinoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunother (1991)

DOI

ISSN

1053-8550

Publication Date

April 1992

Volume

11

Issue

3

Start / End Page

184 / 190

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Middle Aged
  • Male
  • Killer Cells, Lymphokine-Activated
  • Kidney Neoplasms
  • Interleukin-2
  • Infusions, Intravenous
  • Immunotherapy, Adoptive
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Foon, K. A., Walther, P. J., Bernstein, Z. P., Vaickus, L., Rahman, R., Watanabe, H., … Russell, D. (1992). Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J Immunother (1991), 11(3), 184–190. https://doi.org/10.1097/00002371-199204000-00005
Foon, K. A., P. J. Walther, Z. P. Bernstein, L. Vaickus, R. Rahman, H. Watanabe, J. Sweeney, J. Park, D. Vesper, and D. Russell. “Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.J Immunother (1991) 11, no. 3 (April 1992): 184–90. https://doi.org/10.1097/00002371-199204000-00005.
Foon KA, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, et al. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J Immunother (1991). 1992 Apr;11(3):184–90.
Foon, K. A., et al. “Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.J Immunother (1991), vol. 11, no. 3, Apr. 1992, pp. 184–90. Pubmed, doi:10.1097/00002371-199204000-00005.
Foon KA, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, Sweeney J, Park J, Vesper D, Russell D. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J Immunother (1991). 1992 Apr;11(3):184–190.

Published In

J Immunother (1991)

DOI

ISSN

1053-8550

Publication Date

April 1992

Volume

11

Issue

3

Start / End Page

184 / 190

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Middle Aged
  • Male
  • Killer Cells, Lymphokine-Activated
  • Kidney Neoplasms
  • Interleukin-2
  • Infusions, Intravenous
  • Immunotherapy, Adoptive
  • Humans
  • Female